126 related articles for article (PubMed ID: 8403824)
1. The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes.
Groop PH; Melander A; Groop LC
Diabet Med; 1993; 10(7):633-7. PubMed ID: 8403824
[TBL] [Abstract][Full Text] [Related]
2. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
3. The relationship between early insulin release and glucose tolerance in healthy subjects.
Groop PH; Melander A; Groop LC
Scand J Clin Lab Invest; 1993 Jul; 53(4):405-9. PubMed ID: 8378744
[TBL] [Abstract][Full Text] [Related]
4. Extrapancreatic effects of a sulphonylurea. Decrease in xylose absorption by glipizide in type II diabetics.
Kollind M; Adamson U; Lins PE; Ohlsén P
Acta Med Scand; 1984; 215(5):443-5. PubMed ID: 6377829
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
[TBL] [Abstract][Full Text] [Related]
6. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study.
Groop LC; Ratheiser K; Luzi L; Melander A; Simonson DC; Petrides A; Bonadonna RC; Widén E; DeFronzo RA
Acta Diabetol; 1991; 28(2):162-8. PubMed ID: 1777653
[TBL] [Abstract][Full Text] [Related]
7. First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal test.
Rave K; Sidharta PN; Dingemanse J; Heinemann L; Roggen K
Diabetes Technol Ther; 2010 Feb; 12(2):117-23. PubMed ID: 20105041
[TBL] [Abstract][Full Text] [Related]
8. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
Scheen AJ; Lefebvre PJ; Luyckx AS
Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
[TBL] [Abstract][Full Text] [Related]
9. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
Ahrén B; Lundquist I; Scherstén B
Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus.
Bitzén PO; Melander A; Scherstén B; Svensson M; Wåhlin-Boll E
Eur J Clin Pharmacol; 1992; 42(1):77-83. PubMed ID: 1541320
[TBL] [Abstract][Full Text] [Related]
11. The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.
Bitzén PO; Melander A; Scherstén B; Wåhlin-Boll E
Eur J Clin Pharmacol; 1988; 35(1):31-7. PubMed ID: 3065086
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions.
de Souza CJ; Russo P; Lozito R; Dunning BE
Diabetes Obes Metab; 2001 Apr; 3(2):73-83. PubMed ID: 11298729
[TBL] [Abstract][Full Text] [Related]
13. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
de Souza CJ; Gagen K; Chen W; Dragonas N
Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
[TBL] [Abstract][Full Text] [Related]
14. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis.
Coates PA; Ollerton RL; Luzio SD; Ismail I; Owens DR
Diabetes Res Clin Pract; 1994 Dec; 26(3):177-87. PubMed ID: 7736898
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
16. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
17. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
[TBL] [Abstract][Full Text] [Related]
19. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
[TBL] [Abstract][Full Text] [Related]
20. Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes.
Ravanam A; Jeffery J; Nehlawi M; Abraira C
Metabolism; 1991 Nov; 40(11):1173-7. PubMed ID: 1943745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
